Specifically, DCF at a clinically relevant concentration of 10 μM was shown to increase OCT-1 activity and to statistically significantly reduce the IC50 of imatinib in two CML cell lines (K562 and KU812). Here, SLC22A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.